Qiagen announced on April 15 2026 the launch of its CE‑IVDR‑certified QIAstat‑Dx BCID GPF Plus AMR Panel, a new syndromic testing solution for bloodstream infections. The panel expands the QIAstat‑Dx platform, adding 20 pathogen targets and 10 antimicrobial‑resistance markers, and delivers results in about an hour.
The QIAstat‑Dx platform has grown rapidly, with sales up 24% at constant exchange rates in 2025 and an installed base exceeding 5,200 instruments. The new panel extends the platform beyond its previous focus on respiratory, gastrointestinal, and meningitis/encephalitis testing, positioning Qiagen to capture the growing sepsis market.
The launch aligns with Qiagen’s growth‑pillars strategy, which includes QIAstat‑Dx, QuantiFERON, QIAcuity, and QIAGEN Digital Insights. The addition of the BCID GPF Plus AMR Panel is expected to accelerate the platform’s revenue contribution, building on the 15% Q4 2025 growth and the 24% full‑year 2025 growth.
In its Q4 2025 earnings call, CEO Thierry Bernard highlighted the company’s disciplined execution and the strength of its growth pillars, noting that the QIAstat‑Dx platform grew at 8% at constant exchange rates. CFO Roland Sackers emphasized the company’s ability to deliver results above outlook, citing disciplined cost control and a balanced portfolio.
The launch coincides with the ESCMID Global 2026 Congress in Munich (April 17‑21), where Qiagen will showcase its expanded infectious‑disease portfolio. The CE‑IVDR certification ensures market access across Europe, supporting the company’s strategy to expand its presence in the rapidly growing syndromic‑testing market.
While the announcement does not alter Qiagen’s 2026 guidance, it reinforces the company’s confidence in its growth pillars and its ability to capture new market segments. The panel’s rapid turnaround and comprehensive resistance profiling are expected to enhance clinical decision‑making and support antimicrobial‑stewardship initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.